Ann: Kidney Disease Drug Candidate Progressing to Human Trials, page-19

First 19 Last

Share
Profile

Follow
travelbug2

6,554 Posts.

329

23/04/24

10:18

Post #: 73470902
Share

Originally posted by TripAces: ↑

Some interesting points from E & P's note today as the results were better than anticpated:

• To put this result into context: Sarepta’s (NASDAQ:SRPT) drug candidate (SRP-5051; a similar peptide-conjugated oligonucleotide to PYC-003) for Duchenne muscular dystrophy (DMD) also showed a dose dependent and sustained exposure persisting for 28 days, but from double the initial dose (60 mg/kg) and at fraction of the concentration in muscle tissue (~500 ng/mL) that PYC observed in the kidneys at an equivalent time point (>30,000 ng/mL; the actual concentration was above the quantitation limit of the assay).
• Importantly, SRP-5051 at this markedly reduced PD profile to PYC-003 was able to generate ~20% exon skipping.
• Based on these data, PYC-003 could achieve day-30 target tissue concentrations orders of magnitude greater than SRP-5051.
• Obviously PKD and DMD are different conditions in different target organs, but the pharmacodynamic implications of this comparison are relevant and encouraging.
• Taken together, this suggests that PYC-003 could be dosed and tolerated well above the putative therapeutic range (1 – 5 mg/kg), achieving impressive target tissue concentrations, with significant safety headroom.

Expand

this makes me wonder just how much our platform is actually worth!

Originally posted by TripAces: ↑

Some interesting points from E & P's note today as the results were better than anticpated:

• To put this result into context: Sarepta’s (NASDAQ:SRPT) drug candidate (SRP-5051; a similar peptide-conjugated oligonucleotide to PYC-003) for Duchenne muscular dystrophy (DMD) also showed a dose dependent and sustained exposure persisting for 28 days, but from double the initial dose (60 mg/kg) and at fraction of the concentration in muscle tissue (~500 ng/mL) that PYC observed in the kidneys at an equivalent time point (>30,000 ng/mL; the actual concentration was above the quantitation limit of the assay).
• Importantly, SRP-5051 at this markedly reduced PD profile to PYC-003 was able to generate ~20% exon skipping.
• Based on these data, PYC-003 could achieve day-30 target tissue concentrations orders of magnitude greater than SRP-5051.
• Obviously PKD and DMD are different conditions in different target organs, but the pharmacodynamic implications of this comparison are relevant and encouraging.
• Taken together, this suggests that PYC-003 could be dosed and tolerated well above the putative therapeutic range (1 – 5 mg/kg), achieving impressive target tissue concentrations, with significant safety headroom.

Expand

PYC Price at posting: 9.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM

PAM secures high-grade Chilean copper play in strong territory

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

There are more pages in this discussion • 10 more messages in this thread...

First 19 Last

Add PYC (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change -0.005(4.76%)		Mkt cap ! $466.6M

Open	High	Low	Value	Volume
10.0¢	10.5¢	9.8¢	$519.2K	5.169M

Buyers (Bids)

No.	Vol.	Price($)
2	182466	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	101115	2

View Market Depth

No.	Vol.	Price($)
2	182466	0.100
1	51207	0.099
1	306122	0.098
1	10000	0.097
2	100000	0.096

Price($)	Vol.	No.
0.105	101115	2
0.110	602951	8
0.115	585111	3
0.120	639650	5
0.125	390197	4

Last trade - 16.10pm 29/07/2024 (20 minute delay)

PYC (ASX) Chart

Ann: Kidney Disease Drug Candidate Progressing to Human Trials, page-19

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Kidney Disease Drug Candidate Progressing to Human Trials, page-19

Top Stories

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News